<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03262792</url>
  </required_header>
  <id_info>
    <org_study_id>VL/170105/PA/OA</org_study_id>
    <nct_id>NCT03262792</nct_id>
  </id_info>
  <brief_title>Assessment of the Efficacy of Andrographis Paniculata in Subjects With Mild to Moderate Osteoarthritis</brief_title>
  <acronym>A Paniculata</acronym>
  <official_title>A Double-blind, Randomized, Placebo Controlled Study to Assess the Efficacy of Andrographis Paniculata in Subjects With Mild to Moderate Osteoarthritis Over a 12-weeks Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vedic Lifesciences Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vedic Lifesciences Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12 weeks randomized, double-blind, placebo-controlled clinical study to assess the&#xD;
      effect of Andrographis Paniculata at low dose of 300 mg/day and high dose of 600 mg/day in&#xD;
      the study population in the age range of 40-70 years and suffering from mild-moderate OA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, we will assess the efficacy parameters such as effect on various joint health&#xD;
      parameters (pain, stiffness and physical activity) by using WOMAC scale. The individuals with&#xD;
      knee OA suffer from an increased impact on their activities of daily living, which leads to&#xD;
      losses in labor relations, leisure, social life, and sleeping quality, leading also to&#xD;
      important decrease in their quality of life. Thus, an important outcome to be evaluated in&#xD;
      this study is quality of life of these individuals which will be assessed by SF-36&#xD;
      self-reported questionnaire. One of the aims of this study is therefore to investigate the&#xD;
      levels of different dimensions of fatigue in knee OA and to assess changes in fatigue after&#xD;
      the treatment targeting pain reduction and physical functioning by the use of FACIT-fatigue&#xD;
      questionnaire.&#xD;
&#xD;
      Effect of the treatment on rescue medication consumption which is directly proportional to&#xD;
      the degree of pain will also be captured via this study. The hepatic (SGOT and SGPT) and&#xD;
      renal (serum creatinine) safety biomarkers will be assessed to investigate the effect of&#xD;
      chronic use of Andrographis Paniculata on liver and kidneys.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 13, 2017</start_date>
  <completion_date type="Actual">August 27, 2018</completion_date>
  <primary_completion_date type="Actual">July 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo controlled, parallel groups study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WOMAC pain score</measure>
    <time_frame>84 days</time_frame>
    <description>Change in WOMAC pain score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WOMAC stiffness score</measure>
    <time_frame>84 days</time_frame>
    <description>Change in WOMAC stiffness score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC physical function score</measure>
    <time_frame>84 days</time_frame>
    <description>Change in WOMAC physical function score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36</measure>
    <time_frame>84 days</time_frame>
    <description>Change in SF-36's various component scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FACIT score</measure>
    <time_frame>84 days</time_frame>
    <description>Change in FACIT score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication consumption</measure>
    <time_frame>84 days</time_frame>
    <description>Change in rescue medication consumption.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Microcrystalline cellulose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Andrographis Paniculata 150</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Andrographis Paniculata 150 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Andrographis Paniculata 300</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Andrographis Paniculata 300 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Microcrystalline cellulose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Andrographis Paniculata</intervention_name>
    <description>Andrographis Paniculata 150 mg</description>
    <arm_group_label>Andrographis Paniculata 150</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Andrographis Paniculata</intervention_name>
    <description>Andrographis Paniculata 300 mg</description>
    <arm_group_label>Andrographis Paniculata 300</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects in the age range of 40 - 70 years (both inclusive).&#xD;
&#xD;
          2. Body mass index (BMI) must be â‰¥ 25 and &lt; 29.9 kg/m2.&#xD;
&#xD;
          3. Radiographic evidence of grade I- II osteoarthritis of knee joint, based on the&#xD;
             Kellgren and Lawrence radiographic entry criteria with WOMAC pain score in range of&#xD;
             10-16.&#xD;
&#xD;
          4. History of primary idiopathic osteoarthritis of the knee characterized by pain of mild&#xD;
             to moderate intensity which requires intake of analgesics.&#xD;
&#xD;
          5. Self-reported difficulty in at least one of the following activities attributed to&#xD;
             knee pain: walking a distance of 400 metres, getting in and out of the car, going up&#xD;
             and down the stairs or stiffness observed in the knee if &gt; 30 minutes in the same&#xD;
             position.&#xD;
&#xD;
          6. Female subjects of child-bearing age must be willing to use the accepted methods of&#xD;
             contraception during the course of the study.&#xD;
&#xD;
          7. Ability to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior or ongoing medical conditions (e.g. concomitant illness, psychiatric condition,&#xD;
             alcoholism, drug abuse), medical history, physical findings, ECG findings or&#xD;
             laboratory abnormalities that in the investigator's opinion could adversely affect the&#xD;
             safety of the subject, makes it unlikely that the course of treatment or follow-up&#xD;
             would be completed or could impair the assessment of study results.&#xD;
&#xD;
          2. History of surgery or major trauma to the study joint.&#xD;
&#xD;
          3. History of arthroscopic surgery or intervention on the study joint.&#xD;
&#xD;
          4. Subjects who have received intra-articular steroids or hyaluronic acid within the last&#xD;
             three months.&#xD;
&#xD;
          5. Signs of active study joint inflammation including redness, warmth, and/or, if&#xD;
             qualifying with osteoarthritis of the knee, a large, bulging effusion of the study&#xD;
             knee joint with the loss of normal contour of the joint at the screening visit or at&#xD;
             the baseline examination after the washout period.&#xD;
&#xD;
          6. Subjects awaiting a replacement of knee or hip joint.&#xD;
&#xD;
          7. Subjects with other conditions that cause pain.&#xD;
&#xD;
          8. Subjects with deformity of the knee joint.&#xD;
&#xD;
          9. Subject who are significantly incapacitated or disabled and would be categorized as&#xD;
             ACR Functional Class IV (largely or wholly incapacitated), or unable to walk without&#xD;
             assistive devices.&#xD;
&#xD;
         10. Subjects with other known rheumatic or inflammatory disease such as rheumatoid&#xD;
             arthritis, osteomyelitis and bone metastasis.&#xD;
&#xD;
         11. Other pathologic lesions on X-rays of knee.&#xD;
&#xD;
         12. Positive hepatitis B surface antigen, Hepatitis C antibody, Anti human&#xD;
             immunodeficiency virus (HIV) antibody test, or VDRL.&#xD;
&#xD;
         13. History of bleeding disorders.&#xD;
&#xD;
         14. Inability to comply with the protocol requirements.&#xD;
&#xD;
         15. Participation in any other clinical trial within 3 months of registering in this&#xD;
             trial.&#xD;
&#xD;
         16. Women of child-bearing potential with a positive pregnancy test or who are lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shalini Srivastava, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vedic Lifesciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nidaan Hospital, A/1, Adinath Society, Near Dosti Estate, Opposite Antop Hill Post Office, Wadala(West)</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400031</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ayush nursing Home, Gaurav vista, Gaurav Garden,BunderpakhadiRoad, Kandivali(West)</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400067</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siddhant Clinic, Shop No. 17, Lenyadri Cooperative Housing Society, Sector 19A, Nerul(East),Navi Mumbai -400706, Maharashtra</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400706</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopaedic Clinic, 213, 2nd floor, Shiv Centre, Plot no. 72, Sector-17, Vashi, Navi Mumbai.</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://hpingredients.com/products/premier-ingredients/paractin/</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 23, 2017</study_first_submitted>
  <study_first_submitted_qc>August 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2017</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Andrographolide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

